The partners of the LiquiDx project gathered on 18 September 2025 at the Biobanco del Sistema Sanitario Público de Andalucía (BBSSPA) facilities in Granada for the final face-to-face project meeting. Sessions, also broadcast via videoconference, served to review progress in developing an RNA-based liquid biopsy tool for the early detection of five major cancers: lung, colon, breast, prostate, and pancreas.
During the meeting, lessons learned regarding plasma sample quality requirements and strategies to mitigate batch effects in biomarker discovery were shared. The meeting concluded with discussions on preparing the final technical report and a guided tour of BBSSPA’s facilities.
The LiquiDx project has made a significant step forward in the innovation of cfRNA-based liquid biopsies, combining next-generation sequencing, bioinformatics, and precision medicine solutions to create a cutting-edge diagnostic platform for clinical use.
Leitat participated in these developments as member of the consortium, which highlight the commitment to early cancer detection and accelerating the translation of new technologies into accessible clinical tools.
The main outcomes of the project are also planned to be shared with the scientific community through a scientific publication.
Project CPP2021-008897 funded by the Ministry of Science and Innovation.
